A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this study is to determine the 2-year survival rate of both of the chemotherapy regimens in patients with inoperable non-small-cell lung cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Carboplatin; Cisplatin; Pemetrexed

Criteria

Inclusion Criteria:

• Inoperable non small cell lung cancer

• No weight loss greater than 10% in 3 months prior to enrolling in trial

• Adequate kidney function

• Adequate liver function

• Adequate lung function

Exclusion Criteria:

• Previous surgery to remove lung tumor

• Previous chemotherapy or radiation therapy or lung cancer

• Inability to take vitamin supplementation

• Heart attack within past 6 months

• Active infection